SKYRIZI Market Insights

Key Factors Driving SKYRIZI Growth

1. Exceptional revenue growth and blockbuster scale

• 2024 global sales: ~$11.7 billion (~51% YoY growth)

• 2025 global sales: ~$5.0 billion (partial year reported, ~32% YoY growth)

• 2023 → 2024 growth: $3.78B → $11.7B (rapid multi-year expansion)

2. Broad multi-indication expansion (psoriasis → IBD → beyond)

• Approved across:

o Plaque psoriasis (core market)

o Psoriatic arthritis

o Crohn’s disease and ulcerative colitis (IBD expansion)

• IBD approvals significantly expanded addressable population and growth runway

3. Best-in-class IL-23 efficacy and durable response

• SKYRIZI targets IL-23 (p19 subunit), a validated pathway in autoimmune diseases

• Clinical studies show:

o High rates of skin clearance (PASI 90/100) in psoriasis

o Strong endoscopic and clinical remission in Crohn’s disease (published trials)

4. Strategic replacement of Humira (loss-of-exclusivity tailwind)

• Humira faced major biosimilar erosion (U.S. LOE in 2023)

• SKYRIZI + Rinvoq are positioned as next-generation growth drivers

• AbbVie guidance:

o Combined SKYRIZI + Rinvoq expected to exceed $31B annually by 2027

5. Strong uptake in gastroenterology (IBD leadership)

• SKYRIZI gaining significant traction in IBD:

o Reported ~75% frontline share in some IBD settings (company commentary)

• IBD is a large, chronic, high-value biologic market

6. Favorable dosing and patient convenience

• Maintenance dosing:

o Every 8–12 weeks (subcutaneous) after induction

• Compared to older biologics requiring:

o More frequent injections or infusions

7. Strong positioning within AbbVie’s immunology franchise

• Immunology portfolio remains core to AbbVie:

o USD 26.7B total immunology revenue (2024)

• SKYRIZI is now the largest single product contributor in this segment

 

SKYRIZI Recent Developments

• In March 2026, AbbVie announced positive topline results from the Phase III AFFIRM study, where subcutaneous (SC) SKYRIZI achieved superior clinical remission (55% vs. 30%) and endoscopic response (44% vs. 14%) at week 12 compared to placebo.

 

“SKYRIZI Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of SKYRIZI for approved indication like Crohn’s disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, Ulcerative colitis; as well as potential indication like Palmoplantar pustulosis, Atopic dermatitis, and Hidradenitis suppurativa in the 7MM. A detailed picture of SKYRIZI’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the SKYRIZI for approved and potential indications. The SKYRIZI market report provides insights about SKYRIZI’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current SKYRIZI performance, future market assessments inclusive of the SKYRIZI market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of SKYRIZI sales forecasts, along with factors driving its market.

 

SKYRIZI Drug Summary

SKYRIZI is a humanized monoclonal antibody developed by AbbVie that selectively targets the p19 subunit of interleukin-23 (IL-23), a key cytokine involved in inflammatory and immune-mediated diseases. By inhibiting IL-23 signaling, SKYRIZI reduces downstream inflammatory pathways and helps control chronic inflammation. It is approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, demonstrating high rates of skin clearance and durable remission in clinical trials. The drug is administered via subcutaneous injection (with an intravenous induction regimen for inflammatory bowel disease), typically with infrequent maintenance dosing (every 8–12 weeks depending on indication), offering convenience compared to more frequently dosed biologics. Clinical studies have shown strong efficacy and a favorable safety profile, with low immunogenicity and sustained long-term responses, positioning SKYRIZI as a leading IL-23 inhibitor in both dermatology and gastroenterology. The report provides SKYRIZI’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the SKYRIZI Market Report

The report provides insights into:

• A comprehensive product overview including the SKYRIZI MoA, description, dosage and administration, research and development activities in approved indications like Crohn’s disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, Ulcerative colitis; as well as potential indication like Palmoplantar pustulosis, Atopic dermatitis, and Hidradenitis suppurativa.

• Elaborated details on SKYRIZI regulatory milestones and other development activities have been provided in SKYRIZI market report.

• The report also highlights SKYRIZI‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.

• The SKYRIZI market report also covers the patents information, generic entry and impact on cost cut.

• The SKYRIZI market report contains current and forecasted SKYRIZI sales for approved and potential indications till 2034.

• Comprehensive coverage of the late-stage emerging therapies for respective indications.

• The SKYRIZI market report also features the SWOT analysis with analyst views for SKYRIZI in approved and potential indications.

 

Methodology

The SKYRIZI market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

 

SKYRIZI Analytical Perspective by DelveInsight

• In-depth SKYRIZI Market Assessment

This SKYRIZI sales market forecast report provides a detailed market assessment of SKYRIZI for approved indication like Crohn’s disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, Ulcerative colitis; as well as potential indication like Palmoplantar pustulosis, Atopic dermatitis, and Hidradenitis suppurativa in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted SKYRIZI sales data uptil 2034.

• SKYRIZI Clinical Assessment

The SKYRIZI market report provides the clinical trials information of SKYRIZI for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

SKYRIZI Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

SKYRIZI Market Potential & Revenue Forecast

• Projected market size for the SKYRIZI and its key indications

• Estimated SKYRIZI sales potential (SKYRIZI peak sales forecasts)

• SKYRIZI Pricing strategies and reimbursement landscape

SKYRIZI Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)

• SKYRIZI Market positioning compared to existing treatments

• SKYRIZI Strengths & weaknesses relative to competitors

SKYRIZI Regulatory & Commercial Milestones

• SKYRIZI Key regulatory approvals & expected launch timelines

• Commercial partnerships, licensing deals, and M&A activity

SKYRIZI Clinical Differentiation

• SKYRIZI Efficacy & safety advantages over existing drugs

• SKYRIZI Unique selling points  

SKYRIZI Market Report Highlights

• In the coming years, the SKYRIZI market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.

• The SKYRIZI companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence SKYRIZI’s dominance.

• Other emerging products for Crohn’s disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, Ulcerative colitis; as well as potential indication like Palmoplantar pustulosis, Atopic dermatitis, and Hidradenitis suppurativa are expected to give tough market competition to SKYRIZI and launch of late-stage emerging therapies in the near future will significantly impact the market.

• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of SKYRIZI in approved and potential indications.

• Analyse SKYRIZI cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.

• Our in-depth analysis of the forecasted SKYRIZI sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of SKYRIZI in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of SKYRIZI? How strong is SKYRIZI’s clinical and commercial performance?

• What is SKYRIZI’s clinical trial status in each individual indications such as Crohn’s disease, Plaque psoriasis, Psoriasis, Psoriatic arthritis, Ulcerative colitis; as well as potential indication like Palmoplantar pustulosis, Atopic dermatitis, and Hidradenitis suppurativa and study completion date?

• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the SKYRIZI Manufacturers?

• What are the key designations that have been granted to SKYRIZI for approved and potential indications? How are they going to impact SKYRIZI’s penetration in various geographies?

• What is the current and forecasted SKYRIZI market scenario for approved and potential indications? What are the key assumptions behind the forecast?

• What are the current and forecasted sales of SKYRIZI in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan? 

• What are the other emerging products available and how are these giving competition to SKYRIZI for approved and potential indications?

• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?

• How cost-effective is SKYRIZI? What is the duration of therapy and what are the geographical variations in cost per patient?